Panelists discuss how health systems can learn from published case examples when implementing biosimilars, noting that biosimilars can create a “win-win” situation where patients see lower costs, payers see lower charges, and providers may experience better margins.
Health System Implementation and Pricing Strategies
Key Themes:
Key Points for Physicians:
Notable Insights:
The industry trend toward low WAC pricing reflects growing criticism of inflated list prices with large rebates, leading to more transparent pricing models.
Clinical Significance: Biosimilar implementation offers multifaceted financial benefits beyond simple acquisition cost savings, including program eligibility considerations and value optimization across the care continuum.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More